Veru Q1 net loss narrows to $5.3M; cash $33M; Phase 2b obesity trial on track

VERU INC.

Net loss of $5.3M ($0.26 per share) vs $8.9M ($0.61) in Q1 FY2025.
Cash, cash equivalents and restricted cash increased to $33.0M from $15.8M at Sep 30, 2025.
Operating loss from continuing operations improved to $5.4M from $10.2M.
Phase 2b PLATEAU trial of enobosarm+semaglutide in obesity to start Q1 2026; interim analysis Q1 2027.
R&D spend fell to $1.3M from $5.7M; G&A to $4.1M from $5.2M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.